Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **TRAJ46** segment is one of many joining (J) regions encoded in the human T cell receptor alpha (TRA) locus. During T cell development, V (variable) and J (joining) gene segments such as TRAJ46 are randomly recombined to generate the diverse repertoire of T cell receptors (TCRs) on the surface of T lymphocytes. These receptors recognize peptide antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, a fundamental process in adaptive immunity[1][4][5][7][8]. TRAJ46 is therefore essential as a germline element but is not in itself a receptor, protein, or direct drug target. TRAJ46 is a **DNA segment** (a joining region) involved in assembling the TCRα chain and is not a therapeutic target, drug, or biomarker. The **therapeutically relevant target** is the assembled **T cell receptor complex** itself (see "T cell receptor" or "TRAC" for the main protein), not single genetic segments like TRAJ46. If your interest is in the alpha chain of the TCR, the appropriate canonical name would be "T cell receptor alpha chain" or "T cell receptor" (abbreviated TCR or TRAC)[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining segment 46 (TRAJ46).